From Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds
|
|
- Pierce Hardy
- 5 years ago
- Views:
Transcription
1 Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services From Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds Peter D. Kwong AIDS Vaccine 2009, Paris France 22 October 2009
2 How to apply structural biology to vaccine development? Understand HIV mechanisms of humoral immune evasion Understand the manner by which the humoral immune system recognizes HIV Utilize structure-assisted vaccine design to develop immunogens that elicit broadly neutralizing antibodies
3 HIV Viral Spike Has Few Sites of Vulnerability Virus gp41 glycans gp120
4 Sites of Receptor Binding Must Be Conserved Virus CD4 Host cell Co receptor Broadly reactive b12 antibody competes with CD4 to neutralize HIV-1.
5 Structure of b12:gp120 Inner domain gp120 outer domain CDR H3 b12 Heavy chain b12 Light chain Zhou et al.
6 A Site of Vulnerability on HIV-1
7 BUT, Most CD4BS-Antibodies Are Ineffective 1. Current vaccine regiments can elicit CD4BS antibodies, but these are unable to neutralize primary isolates. 2. Many CD4BS monoclonal antibodies characterized and these are ineffective at neutralization. What mechanisms of evasion shield the initial site of CD4 attachment?
8 Structure of an Ineffective CD4BS Antibody 1.5e : YU2 core F91 : YU2 core F105 : JRFL F105 : YU2 core F105 : YU2 (core+v3) m14 : YU2 core m18 : YU2 core F105 : JRFL : G3-42 F105 : JRFL : G3-299 F105 : YU2 (core+v3) : G3-42 F105 : YU2 (core+v3) : G3-299 Crystals X X - Protein Sources: 1.5 e (J. Robinson) F91 (J. Robinson) F105 (M. Posner) m14, m18 (D. Dimitrov) YU2 core (Wyatt) YU2 core+v3 (Wyatt) JRFL (Sodroski) G3-42 (M. Fung) G3-299 (M. Fung) Lei Chen
9 Antibody F105 in Complex with a YU2 gp120 Core with Intact V3 Lei Chen Young Do Kwon
10 Similarity in CD4 and F105 Recognition CD4- binding loop F105-bound CD4-bound D368 R59/100F CD4 F105 Lei Chen Young Do Kwon
11 CD4- Versus F105-Induced Conformation Unliganded F105-induced CD4-induced Bridging sheet is completely opened up Young Do Kwon
12 Under the Bridging Sheet Unliganded F105-induced CD4-induced Movement of bridging sheet uncovers otherwise occluded hydrophobic surface. Young Do Kwon
13 Hydrophobic Immunoprominent Decoy Large hydrophobic glycan-free surface provides an immunoprominent surface to bind antibodies. However, antibodies that bind this surface cannot neutralize. Lei Chen Young Do Kwon
14 Generality of Decoy Covered F105 binding surface by tethering β20/β21 to inner domain Lei Chen Tongqing Zhou
15 Generality of Decoy How does b13 bind gp120? Covering F105 binding surface by tethering β20/β21 to inner domain results in loss of binding for most CD4BS antibodies. Only antibodies b12 and b13 were able to bind to Ds109/428 and OD1 constructs (b12 neutralizes, but b13 does not) Lei Chen
16 b13 Complexed with an HXBc2 gp120 Core Restrained to be in the CD4-Bound State V1/V2 stem gp120 β20/21 b13 Light chain b13 Heavy chain Dennis Burton Ann Hessel Gary Nabel Ling Xu Zhi-Yong Yang Tongqing Zhou
17 Similarity Between b12 and b13 gp120 CDR H2 CD4-binding loop CDR H3 CDR H2 CDR H3 CDR H1 CDR H1 b12 b13 b13 b12 Tongqing Zhou
18 V1/V2 of b12 and b13 b12 V1/V2 V1/V2 b13 Young Do Kwon Tongqing Zhou
19 Modeling Viral Spike Compatibility CD4 (with 17b) F105 EM from Liu et al. Nature 2008 F105- and b13-induced conformations of gp120 are incompatible with the functional viral spikes of most primary HIV-1 isolates. b12 EM from Liu et al Nature 2008 b13 Young Do Kwon Tongqing Zhou
20 Testing gp140 versus gp120 Binding Viral spike mimic: gp140-cleavage minus-foldon trimer is not a precise mimic of the viral spike, but properties should trend in the same direction Lei Chen
21 Similarity of Epitopes and Angles of Approach V1/V2 stem gp120 β20/21 F105 Heavy chain F105 Light chain Despite similarity between CD4, F105, b12 and b13, only CD4 and b12 are able to neutralize effectively b12 Heavy chain b13 Heavy chain b12 Light chain b13 Light chain
22 Precise Targeting Required! The target site is precisely circumscribed by a combination of conformational constraints and N- linked glycosylation. Glycosylation serves to push the immune response toward the bridging sheet. Meanwhile, the surface under the bridging sheet appears to be immunoprominent, and the site of interaction for most CD4BS antibodies. L Chen, Y D Kwon, T Zhou et al. (2009) Science in press.
23 Understand mechanisms of humoral immune evasion Understand manner by which the humoral immune system recognizes HIV Utilize structure assisted vaccine design to develop immunogens that elicit broadly neutralizing antibodies
24 Understand mechanisms of humoral immune evasion Understand manner by which the humoral immune system recognizes HIV Utilize structure assisted vaccine design to develop immunogens that elicit broadly neutralizing antibodies
25 Three Broadly Neutralizing Antibodies Bind to the Membrane Proximal External Region (MPER) of gp41 N-helix C-helix gp NEQELLELDKWASLWNWFNITNWLWYIK 683 2F5 4E10, Z13 1) 2F5 binds membrane proximal region of gp41 (Katinger). 2) 4E10 binds membrane proximal region of gp41 (Katinger). 3) Z13 binds membrane proximal region of gp41 (Burton).
26 Antibody 2F5 with gp41 MPER Epitope 2F5 CDRH3 gp41 2F5 654 EKNEQELLELDKWASLW 670 Gilad Ofek 2004 J. Vriol.
27 Structure of 2F5 Has an Unusual CDR H3 2F5 gp41 2F5 CDRH3 Viral Membrane Does CDR H3 of 2F5 contact membrane?
28 How to apply structural biology to vaccine development? Understand HIV mechanisms of humoral immune evasion Understand the manner by which the humoral immune system recognizes HIV Utilize structure assisted vaccine design to develop immunogens that elicit broadly neutralizing antibodies
29 CD4BS Immune Evasion Acknowledgments Dana-Farber M Posner J Sodroski S-H Xiang X Yang NCI D Dimitrov M-Y Zhang NIAID/NIH J Arthos D Van Ryk Scripps D Burton A Hessel M Zwick U Alabama K Davis G Shaw U Washington D Baker W Schief VRC/NIH L Chen B Dey Y Kwon J Mascola G Nabel X Wu R Wyatt L Xu Z-Y Yang T Zhou
30 VRC/NIH K McKee J Mascola G Nabel G Ofek Y Yang Z-Y Yang Acknowledgments 2F5 CDR H3 Hydrophobicity and Neutralization
31 CEA Loic Martin Claudio Vita Dana-Farber J Sodroski S-H Xiang X Yang NCI D Dimitrov M-Y Zhang NIAID/NIH J Arthos D Van Ryk Acknowledgments Structure-Assisted Immunogen Design Scripps D Burton A Hessel Ian Wilson M Zwick U Alabama K Davis G Shaw U Washington D Baker W Schief IAVI NAC VRC/NIH B Dey J Guenaga L Kong Y Li J Mascola S Majeed G Nabel G Ofek M Pancera M Tang R Wyatt L Xu Z-Y Yang T Zhou
32 Structural analysis reveals the sophisticated camouflage of HIV but also the remarkable abilities of the immune system at recognition. Perhaps if the immune system is aided by a structure-assisted vaccine designed (SAVD) immunogen, a broadly neutralizing response against HIV can be elicited. Adi Ofek (l) & Javier Guenaga (r)
HIV Vaccines: Basic Science
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop
More informationStructural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16
Structural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16 Robert Pejchal, Laura M. Walker, Robyn L. Stanfield, Wayne C. Koff, Sanjay K. Phogat, Pascal Poignard, Dennis
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationCrystal structure of the neutralizing antibody HK20 in complex with its gp41 antigen
Crystal structure of the neutralizing antibody HK20 in complex with its gp41 antigen David Lutje Hulsik Unit for Virus Host Cell Interaction UMI 3265 University Joseph Fourier-EMBL-CNRS, Grenoble Env catalyzed
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationThe challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute
The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200
More information2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.
[Human Vaccines 1:2, 45-60; March/April 2005]; 2005 Landes Bioscience Review Role of Neutralizing Antibodies in Protective Immunity Against HIV Indresh K. Srivastava* Jeffrey B. Ulmer Susan W. Barnett
More informationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target Laura M. Walker, 1 * Sanjay K. Phogat, 2 * Po-Ying Chan-Hui, 3 Denise Wagner, 2 Pham Phung, 4 Julie L. Goss,
More informationAIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
More informationSpike Trimer RNA. dsdna
Spike Trimer RNA dsdna Spike Trimer RNA Spike trimer subunits xxx gp120: receptor and coreceptor binding xxxxxxx gp41: membrane anchoring and target cell fusion dsdna Spike Trimer HIV gp120 binds to host
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationCD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120
CD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120 Colin Wikholm and Isai Lopez BIOL 368: Bioinformatics Laboratory Department of Biology Loyola Marymount University November 15,
More informationModeling Virus- and Antibody-Specific Factors to Predict Human Immunodeficiency Virus Neutralization Efficiency
Article Modeling Virus- and Antibody-Specific Factors to Predict Human Immunodeficiency Virus Neutralization Efficiency Hillel Haim, 1,2 Ignacio Salas, 1 Kathleen McGee, 1 Noah Eichelberger, 2 Elizabeth
More informationNIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
More informationThe Rational Design of an AIDS Vaccine
Leading Edge Essay The Rational Design of an AIDS Vaccine Daniel C. Douek, 1 Peter D. Kwong, 1 and Gary J. Nabel 1, * 1 Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationGlycosylation of the ENV Spike of Primate Immunodeficiency Viruses and Antibody Neutralization
Current HIV Research, 2004, 2, 243-254 243 Glycosylation of the ENV Spike of Primate Immunodeficiency Viruses and Antibody Neutralization Cheryl A. Pikora *1,2 1 Department of Infectious Diseases, Children
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationNonsynonymous Amino Acid Mutations in gp120 Binding Sites are Related to Progression of HIV-1
Nonsynonymous Amino Acid Mutations in gp120 Binding Sites are Related to Progression of HIV-1 Matthew Allegretti and Anindita Varshneya BIOL 368: Bioinformatics Laboratory Loyola Marymount University November
More informationHIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to. the gp41 MPER-directed broadly neutralizing antibody Z13e1
JVI Accepts, published online ahead of print on 17 April 2013 J. Virol. doi:10.1128/jvi.03284-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 HIV-1 envelope glycoprotein
More informationA V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 4-2010 A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2007 Characterization of Human Immunodeficiency Virus Type 1 Monomeric and
More informationYUMI YAMAGUCHI-KABATA AND TAKASHI GOJOBORI* Center for Information Biology, National Institute of Genetics, Mishima , Japan
JOURNAL OF VIROLOGY, May 2000, p. 4335 4350 Vol. 74, No. 9 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Reevaluation of Amino Acid Variability of the Human
More informationRecent Advances on the Use of Structural Biology for the Design of Novel Envelope Immunogens of HIV-1
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2013 Recent Advances on the Use of Structural Biology for the Design of Novel
More informationResearch Online. Edith Cowan University. Constantinos K. Wibmer. Jinal N. Bhiman. Elin S. Gray Edith Cowan University,
Edith Cowan University Research Online ECU Publications 2013 2013 Viral Escape From HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition Of Multiple
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationHHS Public Access Author manuscript Trends Immunol. Author manuscript; available in PMC 2017 June 02.
HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies Steven W. de Taeye 1, John P. Moore 2, and Rogier W. Sanders 1,2 1 Department of Medical Microbiology,
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationChallenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
More informationLow ds/dn Does Not Correlate With High Variation of Amino Acid Sequences Along the gp120 Protein Structure
Low ds/dn Does Not Correlate With High Variation of Amino Acid Sequences Along the gp120 Protein Structure Zach Goldstein & Jordan Detamore BIOL 368: Bioinformatics Laboratory Department of Biology Loyola
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationHIV Vaccine Conference
HIV Vaccine Conference The B cell response to HIV and HIV vaccines: From broadly neutralizing to non-neutralizing antibodies In memory of Dr. Charles Mérieux Organized by Fondation Mérieux Les Pensières
More informationInfection of HIV-1 begins with a series of dynamic binding
pubs.acs.org/biochemistry Spontaneous Rearrangement of the β20/β21 Strands in Simulations of Unliganded HIV 1 Glycoprotein, gp120 Indira H. Shrivastava,*, Kaylee Wendel, and Judith M. LaLonde Department
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationStructure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
CD4 binding induces conformational changes in the gp120 glycoprotein, some of which involve the exposure and/or formation of a binding site for specific chemokine receptors. These chemokine receptors,
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationIdentification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Article Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth Highlights d CD4bs antibody N6 potently neutralizes 98% of HIV isolates d d N6 potently neutralizes
More informationIn Silico Vaccine Design Based on Molecular Simulations of Rhinovirus Chimeras Presenting HIV-1 gp41 Epitopes
doi:10.1016/j.jmb.2008.10.089 J. Mol. Biol. (2009) 385, 675 691 Available online at www.sciencedirect.com In Silico Vaccine Design Based on Molecular Simulations of Rhinovirus Chimeras Presenting HIV-1
More informationDirected Evolution of Peptide Inhibitors of HIV-1 Entry
Directed Evolution of Peptide Inhibitors of HIV-1 Entry The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Accessed Citable
More informationCitation PLoS One, 2013, v. 8 n. 8, p. Article numbere 69789
Title HIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry Author(s) Yuan, T; Li, J; Zhang, M Citation PLoS One, 2013, v. 8 n. 8, p. Article numbere
More informationDEFINING C3-V4 NEUTRALISATION EPITOPES ON HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 SUBTYPE C ENVELOPE GLYCOPROTEINS. Constantinos Kurt Wibmer
DEFINING C3-V4 NEUTRALISATION EPITOPES ON HUMAN IMMUNODEFICIENCY VIRUS TYPE- SUBTYPE C ENVELOPE GLYCOPROTEINS Constantinos Kurt Wibmer Dissertation submitted to the Faculty of Health Sciences, University
More informationIncreased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution
Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution Daniel P. Leaman, Michael B. Zwick* Department of Immunology and Microbial Science, The Scripps Research
More informationCleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design
Article Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design Graphical Abstract Authors Shailendra Kumar Sharma, Natalia de Val,..., Andrew B. Ward, Richard
More informationOverview of the Joint HVTN/HPTN Research Portfolio. Theresa Gamble, PhD HPTN LOC May 15, 2018
Overview of the Joint HVTN/HPTN Research Portfolio Theresa Gamble, PhD HPTN LOC May 15, 2018 1 Joint HVTN/HPTN mab Portfolio HVTN 130/HPTN 089 HVTN 703/HPTN 081 HVTN 704/HPTN 084 AMP (VRC01) HVTN 127/HPTN
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationThe Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions
JOURNAL OF VIROLOGY, Feb. 2009, p. 1649 1659 Vol. 83, No. 4 0022-538X/09/$08.00 0 doi:10.1128/jvi.02046-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. The Human Immunodeficiency
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationStabilization of HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies de Taeye, S.W.
UvA-DARE (Digital Academic Repository) Stabilization of HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies de Taeye, S.W. Link to publication Citation for published version (APA): de
More informationDissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
JOURNAL OF VIROLOGY, June 2007, p. 6548 6562 Vol. 81, No. 12 0022-538X/07/$08.00 0 doi:10.1128/jvi.02749-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Dissecting the Neutralizing
More informationRetrovirology. Open Access RESEARCH
DOI 10.1186/s12977-016-0312-7 Retrovirology RESEARCH Open Access Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly
More informationGP120: Biologic Aspects of Structural Features
Annu. Rev. Immunol. 2001. 19:253 74 Copyright c 2001 by Annual Reviews. All rights reserved GP120: Biologic Aspects of Structural Features Pascal Poignard, Erica Ollmann Saphire, Paul WHI Parren, and Dennis
More informationAffinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Significance
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains Daniela Fera a, Aaron G. Schmidt a, Barton F. Haynes b, Feng Gao b, Hua-Xin Liao b, Thomas B.
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationTargeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein
Targeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
More informationHIV infection is mediated by a series of attachment events
pubs.acs.org/biochemistry Enhanced Dynamics of HIV gp120 Glycoprotein by Small Molecule Binding Indira Shrivastava and Judith M. LaLonde*, Department of Computational and Systems Biology, School of Medicine,
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More informationP450 CYCLE. All P450s follow the same catalytic cycle of;
P450 CYCLE All P450s follow the same catalytic cycle of; 1. Initial substrate binding 2. First electron reduction 3. Oxygen binding 4. Second electron transfer 5 and 6. Proton transfer/dioxygen cleavage
More informationClinical Evaluation the HIV-1 CD4 Binding Site-Specific Monoclonal Antibody VRC01. Barney S. Graham, MD, PhD August 8, 2014
Clinical Evaluation the HIV-1 CD4 Binding Site-Specific Monoclonal Antibody VRC01 Barney S. Graham, MD, PhD August 8, 2014 An Integrated Approach to HIV Vaccine Development MPER CD4bs V1V2 glycan V3 glycan
More informationTranslation. Host Cell Shutoff 1) Initiation of eukaryotic translation involves many initiation factors
Translation Questions? 1) How does poliovirus shutoff eukaryotic translation? 2) If eukaryotic messages are not translated how can poliovirus get its message translated? Host Cell Shutoff 1) Initiation
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationPrevention of infection 2 : immunisation. How infection influences the host : viruses. Peter
Prevention of infection 2 : immunisation How infection influences the host : viruses Peter Balfe, p.balfe@bham.ac.uk @pbalfeuk Let s have some LO s just for fun 1. Define the Immune response to viruses,
More informationBiophysical Characterization of Engineered HIV-1 Immunogen. Derived from gp120 and a Lightweight Scaffolding Protein
Biophysical Characterization of Engineered HIV-1 Immunogen Derived from gp120 and a Lightweight Scaffolding Protein Edgar Faison April 24, 2018 A Thesis Presented in Partial Fulfillment for the Honors
More informationHIV-1 envelope glycoproteins with costimulatory domains for vaccine applications Ik, G.
UvA-DARE (Digital Academic Repository) HIV-1 envelope glycoproteins with costimulatory domains for vaccine applications Ik, G. Link to publication Citation for published version (APA): Ik, G. (2014). HIV-1
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3*
ADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3* 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, University
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationPEPTIDE MARKERS FOR THE HIV-1 NEUTRALIZING ANTIBODY 4ElO. Sondra Lynne Bahr B. Sc., Simon Fraser University, 2000
PEPTIDE MARKERS FOR THE HIV-1 NEUTRALIZING ANTIBODY 4ElO Sondra Lynne Bahr B. Sc., Simon Fraser University, 2000 THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF
More informationX-ray and EM structures of a natively glycosylated HIV-1 envelope trimer
ISSN: 2059-7983 journals.iucr.org/d X-ray and EM structures of a natively glycosylated HIV-1 envelope trimer Harry B. Gristick, Haoqing Wang and Pamela J. Bjorkman Acta Cryst. (2017). D73, 822 828 IUCr
More informationSupplementary Information for. Heavy chain-only IgG2b-llama antibody effects near-pan HIV-1 neutralization by
Supplementary Information for Heavy chain-only IgG2b-llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of co-receptor- and CD4-binding sites
More informationDevelopment of prophylactic vaccines against HIV-1
Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most
More informationCent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France
Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - October 6th to 8th, 2017 Steering Committee Members Françoise Barré-Sinoussi
More informationEngineering of HIV gp120 by Yeast Surface Display for Neutralizing Antibody Characterization and Immunogen Design
Engineering of HIV gp120 by Yeast Surface Display for Neutralizing Antibody Characterization and Immunogen Design by ARCHTV Jordi Mata-Fink B.S., M.S. Chemical Engineering Stanford University, 2005 SUBMITTED
More informationA Blueprint for HIV Vaccine Discovery
A Blueprint for HIV Vaccine Discovery Dennis R. Burton, Scripps Research Institute Rafi Ahmed, Emory University Dan H. Barouch, Beth Israel Deaconess Medical Center Salvatore T. Butera, Scripps Research
More informationHIV-1 envelope glycoproteins with costimulatory domains for vaccine applications Ik, G.
UvA-DARE (Digital Academic Repository) HIV-1 envelope glycoproteins with costimulatory domains for vaccine applications Ik, G. Link to publication Citation for published version (APA): Ik, G. (2014). HIV-1
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationLoyola Marymount University Department of Biology October 25, Zach, Matt, Mia, Will
Alexander M. Andrianov & Ivan V. Anishchenko (2009) Computational Model of the HIV-1 Subtype A V3 Loop: Study on the Conformational Mobility for Structure Based Anti-AIDS Drug Design, Journal of Biomolecular
More informationHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
van den Kerkhof et al. Retrovirology 2013, 10:102 RESEARCH Open Access HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity Tom L G M van den
More informationproteins Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network
proteins STRUCTURE O FUNCTION O BIOINFORMATICS Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network Indira Shrivastava 1 and Judith M. LaLonde 2 1
More informationPreferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after H7N9 immunization in humans
INFECTIOUS DISEASE Preferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after immunization in humans Sarah F. Andrews, 1 * M. Gordon Joyce, 1 Michael J. Chambers,
More informationEmerging Viruses. Part IIb Follow Up from Part I Vaccines and Inhibitors
Emerging Viruses Part IIb Follow Up from Part I Vaccines and Inhibitors Cellular Responses to Viral Invasion: Restriction Factors Cells fight viral infection using a series of restriction factors Restriction
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationGeneration of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells
Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells T. Matt Holl 1, Masayuki Kuraoka 1, Dongmei Liao 1, Laurent Verkoczy 2, M. Anthony Moody 2, Munir
More informationComputational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data
Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data The MIT Faculty has made this article openly available. Please share how this access benefits
More informationA TRIMERIC HIV-1 GP140-BAFF FUSION CONSTRUCT ENHANCES MUCOSAL ANTI- TRIMERIC HIV-1 GP140 IGA IN MICE
A TRIMERIC HIV-1 GP140-BAFF FUSION CONSTRUCT ENHANCES MUCOSAL ANTI- TRIMERIC HIV-1 GP140 IGA IN MICE Jun Liu 1, Kiera Clayton 2, Yu Li 2, Matthew Haaland 2, Jordan Schwartz 2, Hampavi Sivanesan 2, Aamir
More informationUniversity of Cape Town
Neutralizing Antibody Responses in HIV-1 Dual Infection: Lessons for Vaccine Design Daniel James Sheward Supervisor: Carolyn Williamson Co- supervisor: Zenda Woodman Dissertation submitted to the Faculty
More informationThesis for licentiate degree 2010 Dissection of HIV-1 Env-specific B cell responses in non-human primates Christopher Sundling. Christopher Sundling
Thesis for licentiate degree 2010 Thesis for licentiate degree 2010 Dissection of HIV-1 Env-specific B cell responses in non-human primates Christopher Sundling Dissection of HIV-1 Env-specific B cell
More informationTitle: Neutralization resistance of HIV-1 virological synapse-mediated infection is. Running Title: Virological-synapse neutralization resistance
JVI Accepts, published online ahead of print on 2 May 2012 J. Virol. doi:10.1128/jvi.00230-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Title: Neutralization resistance
More informationCrystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)
Ligand Type Name 6 Crystallization-grade After 447-52D After V3 cocktail Receptor CD4 Resonance Units 5 1 5 1 5 1 Broadly neutralizing antibodies 2G12 VRC26.9 Resonance Units Resonance Units 3 1 15 1 5
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationIsolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel
More informationSupporting Information
Supporting Information Guan et al. 10.1073/pnas.1217609110 Fig. S1. Three patterns of reactivity for CD4-induced (CD4i) mabs. The following representative ELISAs show three patterns of reactivity for CD4i
More informationMPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
Published Online: 28 February, 2011 Supp Info: http://doi.org/10.1084/jem.20101907 Downloaded from jem.rupress.org on January 7, 2019 Br ief Definitive Repor t MPER-specific antibodies induce gp120 shedding
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationInvestigation of the genetic differences between bovine herpesvirus type 1 variants and vaccine strains
Investigation of the genetic differences between bovine herpesvirus type 1 variants and vaccine strains Name: Claire Ostertag-Hill Mentor: Dr. Ling Jin Bovine herpesvirus Bovine herpesvirus-1 (BHV-1) Pathogen
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationKymouse, Kymab s human antibody discovery platform, successfully demonstrates steps to developing HIV vaccine
Kymouse, Kymab s human antibody discovery platform, successfully demonstrates steps to developing HIV vaccine Kymab, The Scripps Research Institute and International AIDS Vaccine Initiative collaboration
More information